Ultragenyx agrees to sell rare pediatric priority review voucher for $203 million
The company will transfer a voucher earned from its Sanfilippo syndrome gene therapy approval to an unnamed buyer, pending antitrust clearance.
Ultragenyx Pharmaceutical Inc. disclosed in an 8-K dated October 8, 2026 that it had entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher to a buyer.1 The filing was signed on October 14, 2026 by Howard Horn, the company's Executive Vice President, Chief Financial Officer, Corporate Strategy.
The voucher stems from an FDA approval. The company was awarded the voucher by the FDA on September 17, 2026, upon approval of a therapy for pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A.1 The product, referred to in the filing as "FAYUVITM (rebisufligene etisparvovec-hopf)" and also known as UX111, received this designation in connection with that approval.
Under the terms disclosed, the buyer agreed to pay Ultragenyx $203 million in cash at closing.1 The agreement includes standard legal protections such as representations, warranties, and indemnification terms, though the filing does not specify their scope in detail.
Closing is not yet complete. The deal still needs to clear customary conditions, including the required waiting period under federal antitrust law before the transaction can be finalized.1 Ultragenyx said the full agreement will be filed as an exhibit to its upcoming Annual Report on Form 10-K for the year ended December 31, 2026.1
The filing does not identify the buyer of the voucher, nor does it specify an expected closing date beyond the regulatory conditions noted.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.